Our deals: Complix’s closes Global Drug Development Deal with Jiangsu Nhwa Pharma

Expanding Complix’s revolutionary Cell-Penetrating Alphabody platform beyond oncology & autoimmune diseases

Complix, a Belgian biopharmaceutical company developing a pipeline of transformative Cell-Penetrating Alphabody (CPAB) therapeutics announces that it has signed a second Global Collaboration & License Agreement with a Chinese partner. Jiangsu Nhwa Pharmaceutical Co. (SZ002262), is a leading CNS company in China, with over 4,000 employees,  focused on developing, manufacturing and commercializing innovative drugs in the fields of anesthesia, analgesia, psychiatry and neurology.

Complix and Nhwa will jointly develop novel CPABs capable of crossing the blood brain barrier and cell membrane systems against 2 important CNS disease targets, previously considered undruggable by current drug modalities.

Under the terms of the agreement, Complix will receive upfront license payments and milestone payments as well as royalties on future commercial sales in Greater China. Nhwa will have an exclusive license for Greater China to develop, manufacture and commercialize the CPABs from the collaboration. Both companies retain joint development and commercialization rights for these CPABs in the rest of the world.

The signing of the partnership marks an important milestone for both companies, as the agreement marks Nhwa’s first involvement in the field of macromolecular biopharmaceuticals, while expanding Complix’s CPAB platform beyond oncology, autoimmunity and viral diseases, toward the major disease area of CNS.

How Agio Capital & Business helped

AGIO Capital & Business Solutions successfully helped Complix with identifying key strategic partners in China and actively supported Complix during the partnering discussions and negotiations with Nhwa.

This license deal marks the second Global Licensing deal for Complix with a Chinese partner this year. Both deals were supported by Agio Capital and Business Solutions.

For more information read the full press release.